SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that the SomaScan^® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan^® Platform provides the largest number of protein measurements and the greatest number of orthogonally confirmed protein reagents in the proteomics industry —11,000 protein measurements simultaneously from sample volumes as low as 55 µl—giving researchers access to half of the human proteome in just one assay.

“These new sample types expand the SomaScan11K Platform’s ability to provide important biological insights, supporting translational medicine by advancing research findings into disease causation, clinical pharmacology and drug development,” said Standard BioTools Chief Medical Officer Stephen A. Williams, MD, PhD. “The use of high-throughput proteomics in cerebrospinal fluid for neurodegenerative disease research, for example, is key to providing information on biological changes occurring in the brain. The SomaScan Platform’s sensitivity to these changes is expected to give researchers a wealth of mechanistic neurological data.”

The SomaScan Platform is the only proteomic approach on the market that scales. The precision of the SomaScan Assay has been maintained or improved across all versions, up to and including the most recent release covering 11,000 protein measurements—a challenge that antibody-based assays have failed to overcome. The platform offers low coefficients of variation (CV), a median around 5%, which means the SomaScan Assay can provide more statistical power to make discoveries.

Precision and reproducibility are of paramount importance in clinical trials using precious sample types where pharma customers are using proteomics on this scarce biomaterial for smaller or shorter trials. The SomaScan Platform can supply more data, more precisely, with fewer and smaller volumes of samples such as CSF, cell lysates and tissue homogenates.

“This extension of the SomaScan 11K Assay is part of a continuous improvement effort that will expand the number of reliably measured proteins in various matrices,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “This update will support many of our customers needing the ability to run matched samples to plasma in various sample types, especially in oncology and neurology research.”

Services on these new sample types are now available from Standard BioTools’ CAP/CLIA-certified Services Lab in Boulder, Colo. and from SomaScan^® Authorized Sites around the world. Standard BioTools now offers the new SomaScan 11K Assay, as well as the industry leading single cell proteomics and spatial proteomics solutions (CyTOF^® and Hyperion™ platforms), as a comprehensive services offering to customers who are working to identify biomarkers of predictive response, mechanism of action and patient stratification in their studies.

More information about the new sample types is available at: https://www.somalogic.com/somascan-unique-scale

About Standard BioTools Inc. 

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™. 

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance; expectations, operational and strategic plans; the merger of the Company and SomaLogic; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits following the merger of the Company and SomaLogic. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in Standard BioTools’ business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to Standard BioTools’ research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023, and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023, and in SomaLogic’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law. 

Media Contact
Emilia Costales
720 798 5054
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors
David Holmes
This email address is being protected from spambots. You need JavaScript enabled to view it.